Glenmark Pharma zooms on arm getting USFDA’s approval for Hydrocortisone Valerate Ointment

17 Dec 2018 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 686.85, up by 20.45 points or 3.07% from its previous closing of Rs. 666.40 on the BSE.

The scrip opened at Rs. 668.00 and has touched a high and low of Rs. 690.00 and Rs. 668.00 respectively. So far 12348 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 483.60 on 30-May-2018.

Last one week high and low of the scrip stood at Rs. 684.95 and Rs. 628.05 respectively. The current market cap of the company is Rs. 18803.69 crore.

The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 38.19% and 15.28% respectively.

Glenmark Pharmaceuticals – subsidiary -- Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Hydrocortisone Valerate Ointment USP, 0.2%, a generic version of Westcort Ointment, 0.2%, of Sun Pharmaceutical Industries, Inc.

Glenmark has been granted a competitive generic therapy (CGT) designation for Hydrocortisone Valerate Ointment USP, 0.2%, therefore, with this approval, Glenmark is eligible for 180 days of CGT exclusivity upon commercialization. This is Glenmark’s first granted CGT product approved by the USFDA.

Glenmark Pharma Share Price

1064.90 8.75 (0.83%)
02-May-2024 11:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1527.60
Dr. Reddys Lab 6268.00
Cipla 1420.30
Zydus Lifesciences 964.50
Lupin 1658.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.